Free Trial

SAB Biotherapeutics (SABS) 10K Form and Latest SEC Filings 2026

SAB Biotherapeutics logo
$3.68 -0.01 (-0.27%)
Closing price 04:00 PM Eastern
Extended Trading
$3.63 -0.05 (-1.44%)
As of 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest SAB Biotherapeutics SEC Filings & Recent Activity

SAB Biotherapeutics (NASDAQ:SABS) has submitted 212+ documents to the U.S. Securities and Exchange Commission (SEC) since 2020. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 8-K submitted on May 4, 2026.

Form 4
SAB Biotherapeutics, Inc. Reports Ownership Change on Mar. 25, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
SAB Biotherapeutics Files Current Report on May. 4, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
SAB Biotherapeutics Files Annual Report on Mar. 9, 2026

The 10-K contains SAB Biotherapeutics's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

SAB Biotherapeutics SEC Filing History

Browse SAB Biotherapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/04/2026 3:35 PM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/01/2026 3:57 PM
MILLENNIUM MANAGEMENT LLC (1273087) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13G
04/22/2026 7:13 AM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/31/2026 4:35 PM
SAB Biotherapeutics (1833214) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/25/2026 3:35 PM
Kropotova Alexandra (1825323) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2026 3:25 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13D/A
03/10/2026 6:35 AM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/09/2026 4:10 PM
SAB Biotherapeutics (1833214) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/17/2026 7:47 AM
RTW INVESTMENTS, LP (1493215) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13G/A
02/05/2026 3:45 PM
Bausch Christoph Lawrence (1889981) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 3:50 PM
Reich Samuel J (1394645) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 3:55 PM
SAB Biotherapeutics (1833214) Issuer
Sullivan Eddie Joe (1889712) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2026 3:34 PM
PERCEPTIVE ADVISORS LLC (1224962) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13G
01/07/2026 11:15 PM
SAB Biotherapeutics (1833214) Filer
Form EFFECT
01/07/2026 3:40 PM
SAB Biotherapeutics (1833214) Issuer
ZACCARDELLI DAVID (1627642) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2026 3:41 PM
Jain Rita (1707797) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2026 3:35 PM
SAB Biotherapeutics (1833214) Issuer
ZACCARDELLI DAVID (1627642) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/07/2026 3:36 PM
Jain Rita (1707797) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/07/2026 7:30 AM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/30/2025 9:08 AM
SAB Biotherapeutics (1833214) Filer
Form S-3
Registration statement under Securities Act of 1933  
12/18/2025 3:45 PM
Ellias Helen K. (2001600) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 3:50 PM
Lucera Erick (1697616) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 3:53 PM
Polvino William James (1889459) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 3:40 PM
Link David (2085171) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 3:43 PM
Giberson Scott (1937585) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 3:30 PM
SAB Biotherapeutics (1833214) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
12/12/2025 3:45 PM
Kropotova Alexandra (1825323) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2025 3:45 PM
SAB Biotherapeutics (1833214) Filer
Form 424B3
10/03/2025 3:26 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13D
10/03/2025 3:30 PM
SAB Biotherapeutics (1833214) Subject
Vivo Opportunity Fund Holdings, L.P. (1930214) Filed by
Form SCHEDULE 13G
10/03/2025 3:05 PM
Commodore Capital LP (1831942) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13G
10/01/2025 3:35 PM
Moin Andrew (1996040) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2025 3:06 PM
Petry John (1618702) Reporting
SAB Biotherapeutics (1833214) Issuer
Sessa Capital (0) Master
Sessa Capital GP, LLC (1618699) Reporting
Sessa Capital IM GP, LLC (1618700) Reporting
Sessa Capital IM, L.P. (1595849) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/30/2025 11:15 PM
SAB Biotherapeutics (1833214) Filer
Form EFFECT
09/30/2025 3:35 PM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/26/2025 3:45 PM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/22/2025 4:00 PM
Kropotova Alexandra (1825323) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/22/2025 4:15 PM
SAB Biotherapeutics (1833214) Filer
Form S-3/A
09/02/2025 4:25 PM
SAB Biotherapeutics (1833214) Filer
Form S-3
Registration statement under Securities Act of 1933  
08/29/2025 4:23 PM
SAB Biotherapeutics (1833214) Filer
Form DEF 14A
08/28/2025 4:10 PM
SAB Biotherapeutics (1833214) Issuer
To Lucy (2032049) Reporting
To Lucy (2032049) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/28/2025 4:15 PM
Reich Samuel J (1394645) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025 3:30 PM
SAB Biotherapeutics (1833214) Filer
Form PRE 14A
08/07/2025 6:30 AM
SAB Biotherapeutics (1833214) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/24/2025 3:30 PM
Moin Andrew (1996040) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/24/2025 3:31 PM
Petry John (1618702) Reporting
SAB Biotherapeutics (1833214) Issuer
Sessa Capital (0) Master
Sessa Capital GP, LLC (1618699) Reporting
Sessa Capital IM GP, LLC (1618700) Reporting
Sessa Capital IM, L.P. (1595849) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/21/2025 6:31 AM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/17/2025 4:00 PM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/02/2025 4:00 PM
SAB Biotherapeutics (1833214) Filer
Form DEF 14A
05/09/2025 7:42 AM
SAB Biotherapeutics (1833214) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

SAB Biotherapeutics SEC Filings - Frequently Asked Questions

SAB Biotherapeutics (SABS) has submitted 212+ filings to the SEC since 2020. You can browse the complete history or filter by form type using the tools above.

SAB Biotherapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 8-K submitted on May 4, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:SABS) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners